Ncardia is excited to announce the expansion of their offerings in cardiac safety assessment for drug discovery and development, including the new Ncyte CardioPlate Maestro MEA 96 and two new cardiovascular safety services, at the annual meeting of the Safety Pharmacology Society in Barcelona, Spain.
The Ncyte CardioPlate Maestro MEA 96 is a 96-well plate that arrives pre-plated with differentiated cardiomyocytes and Cardiomyocyte Culture Medium, ready to detect extra-cellular field potentials by multi-electrode array (MEA) technology on the Maestro™ MEA system. Using advanced manufacturing technology, we've optimized the Ncyte CardioPlate for routine use in higher-throughput screening for the assessment of compound effects in human induced pluripotent stem cell-derived cardiomyocytes. Pronounced depolarization and repolarization peaks, low inter- and intrawell beat rate variation, and maximal electrode coverage translate into easier data analysis, less hands-on time, reduced risk of plate failures and labor cost savings.
The new Cardio.Acute Service is a fully standardized MEA safety profiling service that utilizes the new Ncyte CardioPlate Maestro MEA 96. This service is perfomed on a routine basis in our Service division for a fast turnaround time and is immediately available for compound submission. Users of this service benefit from a validated hiPSC-derived cardiomyocyte model and a strict quality controlled assay that can supplement your in-house testing.
Finally, we're excited to announce the launch of the Endothelial Barrier Toxicity Assay - a new assay for the assessment of drug-induced vascular leakage using human iPSC-derived endothelial cells. This latest offering in our Cardiovascular Safety Services offers a highly relevant, sensitive and predictive in vitro safety assessment of drug candidates using functional human endothelial cells derived from human induced pluripotent stem cells. It enables the evaluation of concentration- and time-dependent compound effects using non-invasive real-time data acquisition for such applications as capturing drug induced vascular leakage by chemotherapeutics.
Find out more about each of the three new offers in cardiac safety assessment using the links embedded in the descriptions above.